Immunoproliferative Disorders  >>  CUDC-427  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CUDC-427 / Curis, Roche
NCT01908413: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

Terminated
1
23
US
CUDC-427
Curis, Inc.
Lymphoma
03/15
11/15

Download Options